GHK-Cu vs BPC-157: Dermal Remodelling vs Soft-Tissue Repair
GHK-Cu and BPC-157 are both among the most-studied regenerative peptides in research, but they operate on fundamentally different tissue targets. GHK-Cu (copper peptide) is the gold-standard dermal research compound — collagen synthesis, fibroblast signaling, wound healing, gene-expression modulation. BPC-157 is the gold-standard soft-tissue repair compound — tendons, ligaments, muscle, gut. The overlap is real (both enhance angiogenesis) but the primary research use cases rarely compete.
This comparison helps researchers pick the right tool for their specific tissue model, and flags when the combination stack makes sense.
GHK-Cu
Full entry →- Class
- copper peptide
- Half-life
- ~7 hours subq (topical longer)
- Dose
- 1–3 mg SC/day OR topical solution
- Route
- subq or topical
BPC-157
Full entry →- Class
- healing peptide
- Half-life
- ~4 hours (est., subq)
- Dose
- 250–500 mcg/day
- Route
- subq / IM (local to injury preferred)
Key differences at a glance
| Property | GHK-Cu | BPC-157 |
|---|---|---|
| Primary target tissue | Skin, hair follicles, dermal matrix | Tendons, ligaments, gut, muscle |
| Class | Copper tripeptide | 15-aa healing peptide |
| Mechanism | Collagen I/III synthesis, MMP modulation, SOD upregulation | Growth-factor signaling, NO modulation, angiogenesis |
| Administration | Topical OR SC injection | SC / IM injection (local to injury) |
| Typical dose | 1–3 mg SC/day or 1–2% topical | 250–500 mcg SC/day |
| Gene-expression effect | Modulates ~4,000 human genes (2014 Broad study) | Growth-factor-specific upregulation |
| Best for | Aging skin, hair, wound healing, antioxidant research | Tendon / ligament tears, gut inflammation, muscle repair |
Mechanism: dermal vs musculoskeletal biology
GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) naturally complexed with copper in human plasma. Its concentration drops from ~200 ng/mL at age 20 to ~80 ng/mL by age 60, which is why age-related skin decline maps so cleanly onto GHK-Cu supplementation research. The 2014 Broad Institute study identified GHK-Cu as a modulator of ~4,000 human genes — many involved in DNA repair, antioxidant defense, and inflammatory regulation. This breadth of gene-expression impact is why GHK-Cu is a research tool that intersects multiple aging hallmarks simultaneously.
BPC-157 is a fragment of a protein found in human gastric juice. Its mechanism is more focused — upregulation of specific growth factors (EGF, FGF, VEGF, NGF), modulation of the nitric-oxide system, and local angiogenesis at injury sites. It does not have the gene-expression breadth of GHK-Cu, but it outperforms GHK-Cu substantially in musculoskeletal and gut-repair models.
Stacking for combined research
The cases where both compounds fit one protocol are specific: wound healing research (both enhance angiogenesis, GHK-Cu drives collagen deposition, BPC-157 drives growth-factor signaling), post-surgical skin + soft-tissue recovery, and "beauty stack" protocols where dermal remodeling and soft-tissue repair run in parallel.
For most researchers, pick based on target tissue: skin / hair / dermal aging → GHK-Cu; musculoskeletal / gut / tendon → BPC-157. The overlap is real but narrow.
When to pick each
Pick GHK-Cu when
- Skin-aging, dermal remodeling, photoaging, hair-follicle research.
- Antioxidant / oxidative-stress research (SOD, glutathione upregulation).
- Broad gene-expression research — GHK-Cu modulates thousands of genes.
Pick BPC-157 when
- Tendon, ligament, muscle crush, joint capsule research.
- Gut epithelium / inflammatory research (NSAID lesions, IBD-adjacent).
- Local-injury research where proximal injection matters for efficacy.
Frequently asked
Do GHK-Cu and BPC-157 compete for any receptors?
No. GHK-Cu works largely through direct cellular uptake and gene-expression modulation with copper as a cofactor. BPC-157 works through growth-factor receptor pathways and NO modulation. They can be run in parallel without receptor competition, which is why combined dermal-and-soft-tissue research protocols often use both.
Is topical GHK-Cu as effective as injection?
For dermal research, topical GHK-Cu (1–2% in a vehicle) is the standard route — it is what most published cosmeceutical research uses. Injected GHK-Cu reaches systemic concentrations and is used for research beyond dermatology (wound healing, tissue regeneration). BPC-157 is strictly injectable for meaningful effect.
Which has more published human data?
GHK-Cu has the longer and broader human-data history — more than 40 years of research across dermatology, cosmeceutical science, and cellular-signaling biology. BPC-157 has a growing human-data base but is still more heavily animal-model studied. Both have the analytical standards needed for research-grade protocols.
Can I stack them in a "beauty + recovery" protocol?
Yes — this is one of the canonical combined stacks. GHK-Cu drives collagen and dermal matrix research; BPC-157 supports soft-tissue and vascular repair. Both ship from LifeSpanSupply pre-combined in our Beauty Stack for researchers wanting a protocol-aligned bundle.
Shop GHK-Cu
All products →
Shop BPC-157
All products →
Comparison guides summarize research-context differences. All compounds are chemical reagents for in-vitro research use only. Not for human consumption.